In the staff kitchen at the London biotech start-up Quell Therapeutics, a map of the world is dotted with dozens of coloured pins scattered, from the US, to India, to Mongolia. It’s a jolly leftover from a recent social event where the company’s high-flying scientists played a game of sticking a pin in their home country.
For all the doom and gloom around the UK economy and the lingering concerns over Brexit, it serves as a reminder that Britain is a world leader in advanced medicine, able to attract the brightest minds in the world.
From its base a Imperial College’s new biotech campus in a grim corner of London’s White City, Quell is developing personalised cell engineering technology to calm the body’s autoimmune system,
© Times Media Limited 2023.
Registered in England No. 894646. Registered office: 1 London Bridge Street, SE1 9GF.